PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus to Present at Upcoming Healthcare Conferences
LA JOLLA, Calif. , Feb. 8, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will present a company overview at the following investor conferences:
View HTML
Toggle Summary Regulus Announces Continuation of RG-101 Clinical Hold
FDA requests longer-term follow-up data from ongoing studies
View HTML
Toggle Summary Regulus Announces New Drug Development Candidates
LA JOLLA, Calif. , Dec. 6, 2016 /PRNewswire/ --  Regulus Therapeutics Inc. ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced two new drug development candidates at its R&D day, held in New York .
View HTML
Toggle Summary Regulus to Announce New Drug Development Candidates at R&D Day on December 6, 2016
LA JOLLA, Calif. , Nov. 22, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will host a R&D day on Tuesday, December 6, 2016 from 8:30 a.m.
View HTML
Toggle Summary Regulus Reports Third Quarter 2016 Financial Results
Conference Call Today at 5:00 p.m. ET
View HTML
Toggle Summary Regulus to Release Third Quarter Financial Results on November 1, 2016
Conference Call and Webcast to Follow
View HTML
Toggle Summary Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif. , Oct. 6, 2016 /PRNewswire/ --  Regulus Therapeutics Inc . ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the grant of an inducement stock option to Timothy M. Wright , M.D.
View HTML
Toggle Summary Regulus Appoints Timothy M. Wright, M.D. as Chief Research and Development Officer
LA JOLLA, Calif. , Oct. 5, 2016 /PRNewswire/ -- Regulus Therapeutics Inc . ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Timothy M. Wright , M.D.
View HTML
Toggle Summary Regulus to Present at the 2016 Wells Fargo Healthcare Conference
LA JOLLA, Calif. , Aug. 31, 2016 /PRNewswire/ --  Regulus Therapeutics Inc . ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul C. Grint , M.D., President and Chief Executive Officer of Regulus,
View HTML
Toggle Summary Regulus to Present at the 2016 Wedbush PacGrow Healthcare Conference
LA JOLLA, Calif. , Aug. 9, 2016 /PRNewswire/ --  Regulus Therapeutics Inc . ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Joseph "Jay" Hagan, Chief Operating Officer of Regulus, will present a
View HTML